Clinical trials: Acute Respiratory Infections
COVID-19
Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- KOVIR (NCT05042141)
- Testing
- KOVIR oral capsule
- Where
- Vietnam
- Volunteers
- 66 people
- Sponsor
- Sao Thai Duong Joint Stock Company
COVID-19
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing…
- Trial name
- NCT04960202
- Testing
- PF-07321332, Ritonavir
- Where
- 201 sites in United States, Argentina and 18 more
- Volunteers
- 2,091 people
- Sponsor
- Pfizer
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
Respiratory Infections, Bronchiolitis
An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants
The primary objective of this study is to describe the incidence of RSV-associated LRI among infants <1 year of age presenting to the ED during selected shoulder months.
- Conditions
- Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
- Trial name
- NCT00369759
- Testing
- Emergency Dept. Subjects with LRI or Apnea
- Where
- 38 sites in United States
- Volunteers
- 2,048 people
- Sponsor
- MedImmune LLC
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid19, SARS (Severe Acute Respiratory Syndrome)
Proxalutamide Treatment for Hospitalized COVID-19 Patients
The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04728802
- Testing
- Proxalutamide
- Where
- 8 sites in Brazil
- Volunteers
- 645 people
- Sponsor
- Applied Biology, Inc.
Coronavirus Disease 2019
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.
- Trial name
- NCT04448756
- Testing
- M5049
- Where
- 21 sites in United States, Brazil and 1 more
- Volunteers
- 149 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
SARS (Severe Acute Respiratory Syndrome), COVID-19
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
On January 2020, the discovery of a new coronavirus (SARS-CoV-2) was officially announced by the Chinese health authorities and the World Health Organization (WHO).
- Trial name
- CORSER (NCT04325646)
- Testing
- Human Biological samples
- Where
- 21 sites in France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
Rhinosinusitis, Rhinosinusitis Acute
The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial of the efficacy and safety of Raphamin in the treatment of acute rhinosinusitis in adult patients.
- Trial name
- NCT06901297
- Testing
- Raphamin
- Where
- 44 sites in Russia
- Volunteers
- 552 people
- Sponsor
- Materia Medica Holding
Fever
Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections
The purpose of this study is to assess if a single dose of Diclofenac potassium (0.5 mg/kg) is more or as effective as a single dose of Acetaminophen (10 mg/kg) in the reduction of fever during 2 hours, in the treatment of…
- Trial name
- NCT01019980
- Testing
- Diclofenac potassium, Acetaminophen
- Where
- 2 sites in Venezuela
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Acute Respiratory Infection
Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections
The study is planned to evaluate the therapeutic efficacy and safety of XC8, film-coated tablets, in the treatment of dry non-productive cough on the background of acute respiratory infections in children from 6 to 17 years…
- Trial name
- NCT06379542
- Testing
- XC8
- Where
- 6 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Valenta Pharm JSC
Sepsis, Community-acquired Pneumonia
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute
- Trial name
- NCT04612413
- Testing
- Allocetra-OTS
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- Enlivex Therapeutics Ltd.
COVID-19, SARS-CoV2 Infection
COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests
The aim of the COVAG study (Covid-19 Antigen study) is to assess the diagnostic efficacy of two of the most used rapid antigen tests (Roche \& Abbott).
- Conditions
- COVID-19, SARS-CoV2 Infection, SARS (Disease)
- Trial name
- COVAG (NCT05074017)
- Testing
- 3 nasopharyngeal swab
- Where
- 2 sites in Germany
- Volunteers
- 2,222 people, healthy volunteers welcome
- Sponsor
- Synlab Holding Deutschland GmbH
Covid 19
Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.
This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".
- Trial name
- "BAC-PAC" (NCT04828668)
- Testing
- Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Endourage, LLC
Chronic Bronchitis
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Primary Objective: The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to…
- Trial name
- NCT00132938
- Testing
- telithromycin
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 5,660 people
- Sponsor
- Sanofi
Symptoms of Acute Bronchitis Accompanied by Coughing
Prospan® Hustenzäpfchen - Investigation on Efficacy and Tolerability in Children
The aims of this study are Demonstrating superior efficacy of Prospan® Hustenzäpfchen compared to Placebo in children suffering from acute bronchitis accompanied by coughing Characterisation of safety and tolerability of Prospan®…
- Trial name
- NCT01127048
- Testing
- Suppositories containing Ivy leaves dry extract
- Where
- Germany
- Volunteers
- 1,400 people
- Sponsor
- Engelhard Arzneimittel GmbH & Co.KG
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax